# ER Reactivation Therapy for Breast Cancer

> **NCT02188745** · PHASE2 · COMPLETED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 19 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** 17B-estradiol
- **DRUG:** Letrozole
- **DRUG:** Anastrozole
- **DRUG:** Exemestane

## Key facts

- **NCT ID:** NCT02188745
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-11
- **Primary completion:** 2024-01-05
- **Final completion:** 2024-07-05
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02188745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02188745, "ER Reactivation Therapy for Breast Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02188745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*